a physician a building location a clinical trial a department
menu
BCM - Baylor College of Medicine

Giving life to possible

Changyi Johnny Chen, M.D., Ph.D.

Positions

Professor of Surgery and Chief
Division of Surgical Research
Baylor College of Medicine
Molecular Surgery Endowed Chair
Baylor College of Medicine
Director, Molecular Surgeon Research Center
Molecular Surgeon Research Center
Professor
Molecular and Cellular Biology
Baylor College of Medicine

Education

Ph.D. from Georgia Institute Of Technology
Postdoctoral training from Emory University School Of Medicine
M.S. from University Of Texas At El Paso
Clinical residency training from Southeast University School Of Medicine - Zhong-Da Hospital
M.D. from Southeast University School Of Medicine

Professional Interests

  • Pancreatic cancer
  • PLGA-PEI based nanotechnology
  • Endothelial dysfunction and vascular disease
  • Angiogenesis
  • Atherosclerosis
  • Cardiovascular disease
  • Endothelial nitric oxide synthase
  • Hemodynamics
  • Oxidative stress and antioxidants
  • Vascular tissue engineering

Professional Statement

Dr. Chen's laboratory is actively conducting several basic science and translational research projects that are highly relevant to clinical cardiovascular disease and pancreatic cancer.

Cardiovascular risk factors and their molecular mechanisms in cardiovascular disease:

We are investigating the effects and the molecular mechanisms of several cardiovascular risk factors, including HIV protease inhibitors, the adipokine resistin, soluble CD40L, and uric acid, on biochemical pathways associated with endothelial cell functions. Some of the biochemical pathways under investigation are the endothelial nitric oxide synthase system, the oxidative stress system, and signal transduction pathways. We are carrying on these investigations using several experimental models, such as myographies, organ cultures, mouse models, human tissue samples, and different types of endothelial cells. Based on the molecular mechanisms we uncover, we develop effective therapeutic strategies to treat endothelial dysfunction and atherosclerosis.

Endothelial cell differentiation and angiogenesis:

We are studying the role played by and the molecular mechanisms of hemodynamic factors and several novel molecules on endothelial cells differentiated from embryonic stem cells and from bone marrow-derived stem cells. We are identifying key regulatory genes that trigger endothelial cell differentiation and promote stable angiogenesis. These findings can potentially be applied to the design of novel therapeutic strategies to treat ischemic tissues using genetically engineered endothelial cells. In addition, these studies may provide useful information to genetically engineer novel tissues for vascular grafts.

Pancreatic cancer:

We have been heavily involved in pancreatic cancer research programs for many years. We have several projects focusing on the role and on the mechanisms of several genes, such as microRNA 196a (miR-196a), X-inactive specific transcript (XIST), and Jude-2 in pancreatic cancer. Our comprehensive studies analyze human cancer specimens, clinical outcomes, established cell lines, a nude mouse model, and a genetically engineered mouse model of pancreatic cancer called the KPC model. We are developing PLGA [poly(lactic-co-glycolic acid)]-based nanotechnology for molecular imaging and for specific drug and gene delivery, which has great potential clinical applications, such as molecular diagnostics and targeted therapies.

Selected Publications